

# Muthusamy Kunnimalaiyaan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8958550/publications.pdf>

Version: 2024-02-01

97  
papers

3,333  
citations

126907

33  
h-index

161849

54  
g-index

97  
all docs

97  
docs citations

97  
times ranked

3599  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor Suppressor Role of Notch-1 Signaling in Neuroendocrine Tumors. <i>Oncologist</i> , 2007, 12, 535-542.	3.7	175
2	Current Management of Medullary Thyroid Cancer. <i>Oncologist</i> , 2008, 13, 539-547.	3.7	155
3	Valproic Acid Activates Notch-1 Signaling and Regulates the Neuroendocrine Phenotype in Carcinoid Cancer Cells. <i>Oncologist</i> , 2007, 12, 942-951.	3.7	131
4	Overexpression of the NOTCH1 Intracellular Domain Inhibits Cell Proliferation and Alters the Neuroendocrine Phenotype of Medullary Thyroid Cancer Cells. <i>Journal of Biological Chemistry</i> , 2006, 281, 39819-39830.	3.4	114
5	Co-delivery of doxorubicin and siRNA using octreotide-conjugated gold nanorods for targeted neuroendocrine cancer therapy. <i>Nanoscale</i> , 2012, 4, 7185.	5.6	104
6	Regulation of Neuroendocrine Differentiation in Gastrointestinal Carcinoid Tumor Cells by Notch Signaling. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 4350-4356.	3.6	102
7	Inactivation of glycogen synthase kinase-3 $\beta$ , a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 1151-1158.	4.1	100
8	Resveratrol Induces Differentiation Markers Expression in Anaplastic Thyroid Carcinoma via Activation of Notch1 Signaling and Suppresses Cell Growth. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 1276-1287.	4.1	93
9	Notch 1 signaling is active in ovarian cancer. <i>Gynecologic Oncology</i> , 2010, 117, 130-133.	1.4	89
10	The HDAC Inhibitor Trichostatin A Inhibits Growth of Small Cell Lung Cancer Cells. <i>Journal of Surgical Research</i> , 2007, 142, 219-226.	1.6	86
11	Raf-1 activation suppresses neuroendocrine marker and hormone levels in human gastrointestinal carcinoid cells. <i>American Journal of Physiology - Renal Physiology</i> , 2003, 285, G245-G254.	3.4	83
12	Conservation of the Notch1 signaling pathway in gastrointestinal carcinoid cells. <i>American Journal of Physiology - Renal Physiology</i> , 2005, 289, G636-G642.	3.4	76
13	ZM336372, a Raf-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cells. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 910-917.	4.1	72
14	Valproic Acid Activates Notch1 Signaling and Induces Apoptosis in Medullary Thyroid Cancer Cells. <i>Annals of Surgery</i> , 2008, 247, 1036-1040.	4.2	71
15	Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002. <i>Surgery</i> , 2006, 140, 1009-1015.	1.9	67
16	Valproic Acid Induces Notch1 Signaling in Small Cell Lung Cancer Cells. <i>Journal of Surgical Research</i> , 2008, 148, 31-37.	1.6	62
17	The role of human achaete-scute homolog-1 in medullary thyroid cancer cells. <i>Surgery</i> , 2003, 134, 866-871.	1.9	57
18	Suberoyl Bis-Hydroxamic Acid Activates Notch-1 Signaling and Induces Apoptosis in Medullary Thyroid Carcinoma Cells. <i>Oncologist</i> , 2008, 13, 98-104.	3.7	54

#	ARTICLE	IF	CITATIONS
19	Hesperetin, a potential therapy for carcinoid cancer. <i>American Journal of Surgery</i> , 2011, 201, 329-333.	1.8	52
20	Hairy Enhancer of Split-1 (HES-1), a Notch1 effector, inhibits the growth of carcinoid tumor cells. <i>Surgery</i> , 2005, 138, 1137-1142.	1.9	50
21	Resveratrol Induces Notch2-Mediated Apoptosis and Suppression of Neuroendocrine Markers in Medullary Thyroid Cancer. <i>Annals of Surgical Oncology</i> , 2011, 18, 1506-1511.	1.5	49
22	Identification and validation of Notch pathway activating compounds through a novel high-throughput screening method. <i>Cancer</i> , 2011, 117, 1386-1398.	4.1	49
23	Antiproliferative Effect of Chrysin on Anaplastic Thyroid Cancer. <i>Journal of Surgical Research</i> , 2011, 170, 84-88.	1.6	47
24	Histone deacetylase inhibitors upregulate Notch-1 and inhibit growth in pheochromocytoma cells. <i>Surgery</i> , 2008, 144, 956-962.	1.9	46
25	Xanthohumol Inhibits Notch Signaling and Induces Apoptosis in Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2015, 10, e0127464.	2.5	46
26	Xanthohumol-Mediated Suppression of Notch1 Signaling Is Associated with Antitumor Activity in Human Pancreatic Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1395-1403.	4.1	44
27	Medullary Thyroid Cancer: The Functions of raf-1 and Human Achaete-scute Homologue-1. <i>Thyroid</i> , 2005, 15, 511-521.	4.5	43
28	The Raf-1 pathway: a molecular target for treatment of select neuroendocrine tumors?. <i>Anti-Cancer Drugs</i> , 2006, 17, 139-142.	1.4	43
29	Tautomycetin and tautomycin suppress the growth of medullary thyroid cancer cells via inhibition of glycogen synthase kinase-3 $\beta$ . <i>Molecular Cancer Therapeutics</i> , 2009, 8, 914-920.	4.1	39
30	Analysis of the replicon region and identification of an rRNA operon on pBM400 of <i>Bacillus megaterium</i> QM B1551. <i>Molecular Microbiology</i> , 2001, 39, 1010-1021.	2.5	36
31	Combination Therapy with Histone Deacetylase Inhibitors and Lithium Chloride: A Novel Treatment for Carcinoid Tumors. <i>Annals of Surgical Oncology</i> , 2009, 16, 481-486.	1.5	35
32	Inhibition of Growth in Medullary Thyroid Cancer Cells with Histone Deacetylase Inhibitors and Lithium Chloride. <i>Journal of Surgical Research</i> , 2010, 159, 640-644.	1.6	34
33	Specific glycogen synthase kinase-3 inhibition reduces neuroendocrine markers and suppresses neuroblastoma cell growth. <i>Cancer Biology and Therapy</i> , 2014, 15, 510-515.	3.4	34
34	Antiproliferative and apoptotic effect of LY2090314, a GSK-3 inhibitor, in neuroblastoma in vitro. <i>BMC Cancer</i> , 2018, 18, 560.	2.6	33
35	Chloroplast DNA Replication : Mechanism, Enzymes and Replication Origins. <i>Journal of Plant Biochemistry and Biotechnology</i> , 1997, 6, 1-7.	1.7	32
36	Suberoyl Bishydroxamic Acid Activates Notch1 Signaling and Suppresses Tumor Progression in an Animal Model of Medullary Thyroid Carcinoma. <i>Annals of Surgical Oncology</i> , 2008, 15, 2600-2605.	1.5	31

#	ARTICLE	IF	CITATIONS
37	Inhibition of Phosphatidylinositol 3-Kinase/Akt Signaling Suppresses Tumor Cell Proliferation and Neuroendocrine Marker Expression in GI Carcinoid Tumors. <i>Annals of Surgical Oncology</i> , 2009, 16, 2936-2942.	1.5	31
38	Identification of a Novel Raf-1 Pathway Activator that Inhibits Gastrointestinal Carcinoid Cell Growth. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 429-437.	4.1	31
39	A novel gene panel for prediction of lymph-node metastasis and recurrence in patients with thyroid cancer. <i>Surgery</i> , 2020, 167, 73-79.	1.9	31
40	A Mouse Model of Carcinoid Syndrome and Heart Disease. <i>Journal of Surgical Research</i> , 2005, 126, 102-105.	1.6	30
41	Mitochondria-targeted antioxidant and glycolysis inhibition. <i>Anti-Cancer Drugs</i> , 2013, 24, 881-888.	1.4	29
42	Characterization of replication origins flanking the 23S rRNA gene in tobacco chloroplast DNA. <i>Plant Molecular Biology</i> , 1996, 32, 693-706.	3.9	27
43	Glycogen synthase kinase-3 inhibitor AR-A014418 suppresses pancreatic cancer cell growth via inhibition of GSK-3-mediated Notch1 expression. <i>Hpb</i> , 2015, 17, 770-776.	0.3	27
44	Analysis of the tobacco chloroplast DNA replication origin (ori B) downstream of the 23 S rRNA gene 1 Edited by N. H. Chua. <i>Journal of Molecular Biology</i> , 1997, 268, 273-283.	4.2	26
45	Suberoyl Bishydroxamic Acid Inhibits Cellular Proliferation by Inducing Cell Cycle Arrest in Carcinoid Cancer Cells. <i>Journal of Gastrointestinal Surgery</i> , 2007, 11, 1515-1520.	1.7	26
46	Azacytidine induces cell cycle arrest and suppression of neuroendocrine markers in carcinoids. <i>International Journal of Clinical and Experimental Medicine</i> , 2010, 3, 95-102.	1.3	26
47	Lithium ions: A novel treatment for pheochromocytomas and paragangliomas. <i>Surgery</i> , 2007, 141, 161-165.	1.9	25
48	Phosphatidylinositol 3-Kinase-Akt Signaling in Pulmonary Carcinoid Cells. <i>Journal of the American College of Surgeons</i> , 2009, 209, 82-88.	0.5	25
49	Curcumin-mediated regulation of Notch1/hairy and enhancer of split-1/survivin: molecular targeting in cholangiocarcinoma. <i>Journal of Surgical Research</i> , 2015, 198, 434-440.	1.6	25
50	Xanthohumol inhibits the neuroendocrine transcription factor achaete-scute complex-like 1, suppresses proliferation, and induces phosphorylated ERK1/2 in medullary thyroid cancer. <i>American Journal of Surgery</i> , 2010, 199, 315-318.	1.8	24
51	Sequencing and Characterization of pBM400 from <i>Bacillus megaterium</i> QM B1551. <i>Applied and Environmental Microbiology</i> , 2003, 69, 6888-6898.	3.1	23
52	In-vivo activation of Raf-1 inhibits tumor growth and development in a xenograft model of human medullary thyroid cancer. <i>Anti-Cancer Drugs</i> , 2006, 17, 849-853.	1.4	23
53	Inhibition of the AKT pathway in cholangiocarcinoma by MK2206 reduces cellular viability via induction of apoptosis. <i>Cancer Cell International</i> , 2015, 15, 13.	4.1	23
54	Expression of the Active Notch1 Decreases MTC Tumor Growth In Vivo. <i>Journal of Surgical Research</i> , 2011, 171, 23-27.	1.6	22

#	ARTICLE	IF	CITATIONS
55	Leflunomide suppresses growth in human medullary thyroid cancer cells. <i>Journal of Surgical Research</i> , 2013, 185, 212-216.	1.6	22
56	ZM336372, A Raf-1 Activator, Inhibits Growth of Pheochromocytoma Cells. <i>Journal of Surgical Research</i> , 2006, 133, 42-45.	1.6	21
57	MK2206 inhibits hepatocellular carcinoma cellular proliferation via induction of apoptosis and cell cycle arrest. <i>Journal of Surgical Research</i> , 2014, 191, 280-285.	1.6	21
58	Neuroendocrine phenotype alteration and growth suppression through apoptosis by MK-2206, an allosteric inhibitor of AKT, in carcinoid cell lines in vitro. <i>Anti-Cancer Drugs</i> , 2013, 24, 66-72.	1.4	19
59	Antiproliferative and apoptotic effects of xanthohumol in cholangiocarcinoma. <i>Oncotarget</i> , 2017, 8, 88069-88078.	1.8	19
60	Xanthohumol increases death receptor 5 expression and enhances apoptosis with the TNF-related apoptosis-inducing ligand in neuroblastoma cell lines. <i>PLoS ONE</i> , 2019, 14, e0213776.	2.5	19
61	Required sequence elements for chloroplast DNA replication activity in vitro and in electroporated chloroplasts. <i>Plant Science</i> , 2004, 166, 151-161.	3.6	18
62	Neuroendocrine tumor cell growth inhibition by ZM336372 through alterations in multiple signaling pathways. <i>Surgery</i> , 2007, 142, 959-964.	1.9	18
63	Characterization of the tumor marker muc16 (ca125) expressed by murine ovarian tumor cell lines and identification of a panel of cross-reactive monoclonal antibodies. <i>Journal of Ovarian Research</i> , 2009, 2, 8.	3.0	18
64	Lithium inhibits carcinoid cell growth in vitro. <i>American Journal of Translational Research (discontinued)</i> , 2010, 2, 248-53.	0.0	17
65	Characterization of a Theta Plasmid Replicon with Homology to All Four Large Plasmids of <i>Bacillus megaterium</i> QM B1551. <i>Plasmid</i> , 1998, 40, 175-189.	1.4	16
66	Potential Molecular Targeted Therapeutics: Role of PI3-K/Akt/mTOR Inhibition in Cancer. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2015, 16, 29-37.	1.7	16
67	Novel targets for the treatment and palliation of gastrointestinal neuroendocrine tumors. <i>Current Opinion in Investigational Drugs</i> , 2008, 9, 576-82.	2.3	16
68	Molecular Characterization of Plasmid pBM300 from <i>Bacillus megaterium</i> QM B1551. <i>Applied and Environmental Microbiology</i> , 2005, 71, 3068-3076.	3.1	14
69	In vitro replication of mitochondrial plasmid mp1 from the higher plant <i>Chenopodium album</i> (L.): a remnant of bacterial rolling circle and conjugative plasmids?. <i>Journal of Molecular Biology</i> , 1998, 284, 1005-1015.	4.2	13
70	Tautomycin suppresses growth and neuroendocrine hormone markers in carcinoid cells through activation of the Raf-1 pathway. <i>American Journal of Surgery</i> , 2009, 197, 313-319.	1.8	13
71	MG-132 Inhibits Carcinoid Growth and Alters the Neuroendocrine Phenotype. <i>Journal of Surgical Research</i> , 2010, 158, 15-19.	1.6	13
72	AKT and PTEN expression in human gastrointestinal carcinoid tumors. <i>American Journal of Translational Research (discontinued)</i> , 2009, 1, 291-9.	0.0	13

#	ARTICLE	IF	CITATIONS
73	Regulation of cell-cell contact molecules and the metastatic phenotype of medullary thyroid carcinoma by the Raf-1/MEK/ERK pathway. <i>Surgery</i> , 2008, 144, 920-925.	1.9	12
74	Focal Adhesion Kinase, a Downstream Mediator of Raf-1 Signaling, Suppresses Cellular Adhesion, Migration, and Neuroendocrine Markers in BON Carcinoid Cells. <i>Molecular Cancer Research</i> , 2010, 8, 775-782.	3.4	12
75	Medullary Thyroid Carcinoma: Targeted Therapies and Future Directions. <i>Journal of Oncology</i> , 2009, 2009, 1-7.	1.3	11
76	Inhibition of the PI3K Pathway Suppresses Hormonal Secretion and Limits Growth in Pheochromocytoma Cells. <i>World Journal of Surgery</i> , 2009, 33, 2452-2457.	1.6	10
77	Synergistic Effect of Pasireotide and Teriflunomide in Carcinoids in vitro. <i>Neuroendocrinology</i> , 2013, 97, 183-192.	2.5	10
78	Notch signaling in hepatocellular carcinoma: molecular targeting in an advanced disease. <i>Hepatoma Research</i> , 2015, 1, 11.	1.5	10
79	Suberoylanilide hydroxamic Acid, a histone deacetylase inhibitor, alters multiple signaling pathways in hepatocellular carcinoma cell lines. <i>American Journal of Surgery</i> , 2017, 213, 645-651.	1.8	9
80	Raf-1 activation in gastrointestinal carcinoid cells decreases tumor cell adhesion. <i>American Journal of Surgery</i> , 2007, 193, 331-335.	1.8	8
81	MK-2206 Causes Growth Suppression and Reduces Neuroendocrine Tumor Marker Production in Medullary Thyroid Cancer Through Akt Inhibition. <i>Annals of Surgical Oncology</i> , 2013, 20, 3862-3868.	1.5	8
82	ZM336372, A Raf-1 Activator, Causes Suppression of Proliferation in a Human Hepatocellular Carcinoma Cell Line. <i>Journal of Gastrointestinal Surgery</i> , 2008, 12, 852-857.	1.7	7
83	ZM336372 Induces Apoptosis Associated with Phosphorylation of GSK-3 $\beta$ in Pancreatic Adenocarcinoma Cell Lines. <i>Journal of Surgical Research</i> , 2010, 161, 28-32.	1.6	7
84	Role of Akt inhibition on Notch1 expression in hepatocellular carcinoma: potential role for dual targeted therapy. <i>American Journal of Surgery</i> , 2016, 211, 755-760.	1.8	7
85	Tumor suppressor role of notch1 and raf-1 signaling in medullary thyroid cancer cells. <i>Translational Oncogenomics</i> , 2007, 2, 43-7.	1.7	4
86	Chrysin induces growth suppression through apoptosis in neuroblastoma cells. <i>Journal of the American College of Surgeons</i> , 2012, 215, S70.	0.5	3
87	The Phosphatidylinositol 3-kinase/Akt Signaling Pathway in Neuroendocrine Tumors. <i>Global Journal of Biochemistry</i> , 2012, 3, .	0.5	1
88	A mouse model of carcinoid syndrome and heart disease. <i>Journal of the American College of Surgeons</i> , 2004, 199, 17.	0.5	0
89	Suberoylanilide hydroxamic acid activates Notch1 signaling and induces apoptosis in medullary thyroid cancer cells. <i>Journal of the American College of Surgeons</i> , 2007, 205, S90.	0.5	0
90	PI3K-Akt signaling in pulmonary carcinoid cells. <i>Journal of the American College of Surgeons</i> , 2008, 207, S31.	0.5	0

#	ARTICLE	IF	CITATIONS
91	Tautomycetin suppresses carcinoid tumor growth and bioactive hormone production through inactivation of glycogen synthase kinase-3 beta. Journal of the American College of Surgeons, 2008, 207, S103-S104.	0.5	0
92	Teriflunomide activates the Notch pathway and leads to carcinoid cancer growth suppression by cell cycle arrest. Journal of the American College of Surgeons, 2009, 209, S34.	0.5	0
93	Resveratrol regulates the Notch2-mediated neuroendocrine phenotype in human carcinoid cancer cells. Journal of the American College of Surgeons, 2009, 209, S126.	0.5	0
94	Abstract 4142: The effects of SBHA on Notch 1 expression and platinum sensitivity in ovarian cancer cells. , 2010, , .		0
95	Abstract 3085: Overexpression of theNOTCH3intracellular domain alters neuroendocrine phenotype in carcinoid tumor cells. , 2010, , .		0
96	Abstract 2181: Tumor suppressor role of Notch3 in medullary thyroid carcinoma. , 2011, , .		0
97	Abstract 951: Preclinical evaluation of Xanthohumol in carcinoid cancer growth in vitro and in vivo. , 2012, , .		0